SALL4 and lung carcinoma: Treatment with 10 μM of TAT peptide-tagged SALL4 peptide (TAT-SALL4) led to a 30-50% reduction of cell viability in all three SALL4-positive lung cancer cell lines (H661, H522, and PC-9), while no effect was observed on non-SALL4-expressing H1299 cells, compared to control peptides (TAT, or TAT-Con) (Supplementary Figure S5).